Literature DB >> 22526533

Central administration of oxytocin receptor ligands affects cued fear extinction in rats and mice in a timepoint-dependent manner.

Iulia Toth1, Inga D Neumann, David A Slattery.   

Abstract

RATIONALE: Oxytocin (OXT) has been proposed as a potential therapeutic agent for post-traumatic stress disorder (PTSD).
OBJECTIVES: We aimed to verify whether pharmacological manipulation of the brain OXT system affects cued fear conditioning and fear extinction.
METHODS: Male rats and mice were intracerebroventricularly administered synthetic OXT (rats, 0.1 or 1.0 μg/5 μl; mice, 0.1 or 0.5 μg/2 μl) and/or an OXT receptor antagonist (OXTR-A; rats, 0.75 μg/5 μl) either prior to fear conditioning or extinction training.
RESULTS: Preconditioning administration of OXT did not affect fear conditioning in rats, but decreased fear expression and facilitated fear extinction. In contrast, preconditioning blockade of OXT neurotransmission by OXTR-A did not affect fear conditioning or fear expression, but impaired fear extinction. When administered before extinction training, OXT impaired fear extinction in both rats and mice, indicating that the effects of OXT on fear extinction are conserved across species. This impairment was OXTR-mediated, as the inhibitory effect of OXT on fear extinction was abolished by prior treatment with OXTR-A. The impaired fear extinction was not a result of reduced locomotion in rats, whereas an apparent decrease in fear expression and facilitation of fear extinction with the higher OXT dose in mice was the result of behavioral hyperactivity.
CONCLUSIONS: These results suggest that increasing OXT neurotransmission during traumatic events is likely to prevent the formation of aversive memories. In contrast, OXT treatment before fear extinction training, which would be the comparable timepoint for psychotherapy in PTSD patients, rather delays fear extinction and, therefore, caution is needed before recommending OXT for the treatment of PTSD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526533     DOI: 10.1007/s00213-012-2702-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  75 in total

1.  Brain activation to phobia-related pictures in spider phobic humans: an event-related functional magnetic resonance imaging study.

Authors:  Stefan Dilger; Thomas Straube; Hans-Joachim Mentzel; Clemens Fitzek; Jürgen R Reichenbach; Holger Hecht; Silke Krieschel; Ingmar Gutberlet; Wolfgang H R Miltner
Journal:  Neurosci Lett       Date:  2003-09-04       Impact factor: 3.046

2.  Switching on and off fear by distinct neuronal circuits.

Authors:  Cyril Herry; Stephane Ciocchi; Verena Senn; Lynda Demmou; Christian Müller; Andreas Lüthi
Journal:  Nature       Date:  2008-07-09       Impact factor: 49.962

3.  Stress- and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults.

Authors:  C Kirschbaum; O T Wolf; M May; W Wippich; D H Hellhammer
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

4.  DHEA-S selectively impairs contextual-fear conditioning: support for the antiglucocorticoid hypothesis.

Authors:  M Fleshner; C R Pugh; D Tremblay; J W Rudy
Journal:  Behav Neurosci       Date:  1997-06       Impact factor: 1.912

Review 5.  Psychological treatments for chronic post-traumatic stress disorder. Systematic review and meta-analysis.

Authors:  Jonathan I Bisson; Anke Ehlers; Rosa Matthews; Stephen Pilling; David Richards; Stuart Turner
Journal:  Br J Psychiatry       Date:  2007-02       Impact factor: 9.319

6.  An anxiolytic action of oxytocin is enhanced by estrogen in the mouse.

Authors:  M M McCarthy; C H McDonald; P J Brooks; D Goldman
Journal:  Physiol Behav       Date:  1996-11

Review 7.  Behavioral and neural analysis of GABA in the acquisition, consolidation, reconsolidation, and extinction of fear memory.

Authors:  Steve R Makkar; Shirley Q Zhang; Jacquelyn Cranney
Journal:  Neuropsychopharmacology       Date:  2010-04-21       Impact factor: 7.853

8.  Effect of oxytocin and vasopressin on memory consolidation: sites of action and catecholaminergic correlates after local microinjection into limbic-midbrain structures.

Authors:  G L Kovács; B Bohus; D H Versteeg; E R de Kloet; D de Wied
Journal:  Brain Res       Date:  1979-10-19       Impact factor: 3.252

9.  Glucocorticoid involvement in memory formation in a rat model for traumatic memory.

Authors:  M Isabel Cordero; Nyika D Kruyt; J Joaquin Merino; Carmen Sandi
Journal:  Stress       Date:  2002-02       Impact factor: 3.493

Review 10.  Posttraumatic stress disorder: acquisition, recognition, course, and treatment.

Authors:  Jonathan R T Davidson; Dan J Stein; Arieh Y Shalev; Rachel Yehuda
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2004       Impact factor: 2.198

View more
  36 in total

Review 1.  Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders.

Authors:  Olena Bukalo; Courtney R Pinard; Andrew Holmes
Journal:  Br J Pharmacol       Date:  2014-07-23       Impact factor: 8.739

2.  Distinct oxytocin effects on belief updating in response to desirable and undesirable feedback.

Authors:  Yina Ma; Shiyi Li; Chenbo Wang; Yi Liu; Wenxin Li; Xinyuan Yan; Qiang Chen; Shihui Han
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

Review 3.  Sex differences in fear extinction.

Authors:  E R Velasco; A Florido; M R Milad; R Andero
Journal:  Neurosci Biobehav Rev       Date:  2019-05-23       Impact factor: 8.989

4.  Oxytocin receptor antagonist reverses the blunting effect of pair bonding on fear learning in monogamous prairie voles.

Authors:  Yu Hirota; Aki Arai; Larry J Young; Yoji Osako; Kazunari Yuri; Shinichi Mitsui
Journal:  Horm Behav       Date:  2020-01-24       Impact factor: 3.587

Review 5.  A Precision Medicine Approach to Oxytocin Trials.

Authors:  Elissar Andari; Rene Hurlemann; Larry J Young
Journal:  Curr Top Behav Neurosci       Date:  2018

6.  Oxytocin in the medial prefrontal cortex attenuates anxiety: Anatomical and receptor specificity and mechanism of action.

Authors:  Sara Sabihi; Shirley M Dong; Skyler D Maurer; Caitlin Post; Benedetta Leuner
Journal:  Neuropharmacology       Date:  2017-06-24       Impact factor: 5.250

Review 7.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

8.  Intranasal Oxytocin May Improve High-Level Social Cognition in Schizophrenia, But Not Social Cognition or Neurocognition in General: A Multilevel Bayesian Meta-analysis.

Authors:  Paul-Christian Bürkner; Donald R Williams; Trenton C Simmons; Josh D Woolley
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

9.  Effects of intranasal oxytocin on amygdala reactivity to emotional faces in recently trauma-exposed individuals.

Authors:  Jessie L Frijling; Mirjam van Zuiden; Saskia B J Koch; Laura Nawijn; Dick J Veltman; Miranda Olff
Journal:  Soc Cogn Affect Neurosci       Date:  2015-09-17       Impact factor: 3.436

10.  Brain oxytocin in social fear conditioning and its extinction: involvement of the lateral septum.

Authors:  Iulia Zoicas; David A Slattery; Inga D Neumann
Journal:  Neuropsychopharmacology       Date:  2014-06-26       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.